IL-32 expression is an independent prognostic marker for gastric cancer

Sumiya Ishigami, Takaaki Arigami, Yasuto Uchikado, Tetsuro Setoyama, Yoshiaki Kita, Ken Sasaki, Hiroshi Okumura, Hiroshi Kurahara, Yuko Kijima, Aya Harada, Shinichi Ueno, Shoji Natsugoe

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)


A strong link between inflammation and gastrointestinal cancer has been demonstrated. Interleukin (IL)-32 is a recently described pro-inflammatory cytokine characterized by the induction of nuclear factor kappa B (NF-κB) activation. We investigated whether IL-32 expression has clinical significance in gastric cancer. A total of 182 gastric cancer patients who received curative gastrectomy were enrolled in our study. IL-32 expression was detected by immunohistochemistry, and the correlation between clinicopathological features and IL-32 expression was analyzed. Tumor depth and lymph node metastases developed more frequently in IL-32-positive gastric cancer patients than those who were negative for IL-32 expression (p < 0.01). Lymphatic- and venous invasion in the IL-32-positive group were more severe than in cancer cells lacking IL-32 expression (p < 0.05). Multivariate analysis demonstrated that IL-32 is one of the prognostic markers (p < 0.03) for gastric cancer, in addition to nodal involvement and tumor depth. IL-32 positivity significantly affected clinicopathological factors. Thus, IL-32 expression in gastric cancer may serve as a preferential metastatic condition that allows cells to escape host antitumor immunity. Pro-inflammatory cytokines induce immunosuppression in a paracrine manner, thereby facilitating the metastasis of tumor cells.

Original languageEnglish
Article number472
JournalMedical Oncology
Issue number2
Publication statusPublished - 06-2013
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'IL-32 expression is an independent prognostic marker for gastric cancer'. Together they form a unique fingerprint.

Cite this